Dr. Allison J. Hulme Ph.D. has been appointed as Director of the Company effective 1/1/2020. From January 2005 to October 2009, Dr. Hulme served as Executive Vice President of Autoimmune, Tysabri, Global Development and Head of Autoimmune and Tysabri Franchise at Elan Corporation, plc (also known as Elan Pharmaceuticals), a neuroscience-focused biotechnology company. From October 1995 to January 2005, she served in various roles of increasing responsibility, including, Global Project Leader for Tysabri, Head of Tysabri Business Enterprise and Senior Vice President of Global Development at Elan Pharmaceuticals. Previously, Dr. Hulme held several positions in clinical research at Glaxo Wellcome Pharmaceuticals in the United Kingdom and served as lecturer at Luton University.
As the Director of Sophiris Bio Inc, the total compensation of Allison Hulme at Sophiris Bio Inc is $604,535. There are 1 executives at Sophiris Bio Inc getting paid more, with Randall Woods having the highest compensation of $637,543.
Allison Hulme is 52, he's been the Director of Sophiris Bio Inc since 2020. There are 5 older and 2 younger executives at Sophiris Bio Inc. The oldest executive at Sophiris Bio Inc is Lars Ekman, 70, who is the Chairman of the Board.
Allison's mailing address filed with the SEC is 1258 Prospect St, La Jolla, CA 92037, USA.
Over the last 11 years, insiders at Sophiris Bio Inc have traded over $592,052 worth of Sophiris Bio Inc stock and bought 1,642,180 units worth $8,144,540 . The most active insiders traders include Capital, Llc Boxer Asset Ma..., Capital, Llc Boxer Asset Ma... oraz William R Rohn. On average, Sophiris Bio Inc executives and independent directors trade stock every 155 days with the average trade being worth of $0. The most recent stock trade was executed by Randall E Woods on 19 September 2018, trading 10,000 units of SPHS stock currently worth $26,300.
Sophiris Bio Inc executives and other stock owners filed with the SEC include: